U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C18H21N3O3S
Molecular Weight 359.443
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RABEPRAZOLE

SMILES

COCCCOC1=CC=NC(C[S+]([O-])C2=NC3=C(N2)C=CC=C3)=C1C

InChI

InChIKey=YREYEVIYCVEVJK-UHFFFAOYSA-N
InChI=1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)

HIDE SMILES / InChI

Molecular Formula C18H21N3O3S
Molecular Weight 359.443
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20973lbl.pdf

Rabeprazole sodium was discovered by Eisai Co., Ltd. Janssen Pharmaceutica N.V. and Eisai Co., Ltd. have a strategic alliance in which Eisai and Janssen-Cilag co-promote the drug in Germany and the U.K. In the US rabeprazole sodium is co-promoted under the brand name AcipHex by Eisai Inc. and Janssen Pharmaceutica Inc. Pariet is available through Janssen-Cilag in most other countries excluding Japan and some Asian countries. Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. Rabeprazole is a prodrug and is converted to the active sulphenamide form in the acid environment of the parietal cells. Rabeprazole is used to heal and maintain the healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD), for healing Duodenal Ulcers, and for treatment of pathological hypersecretory conditions such as Zollinger-Ellison Syndrome. Rabeprazole suppresses gastric acid secretion by inhibiting the gastric H+, K+ATPase at the secretory surface of the gastric parietal cell and does not exhibit anticholinergic or histamine H2-receptor antagonist properties. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton-pump inhibitor which blocks the final step of gastric acid secretion. In gastric parietal cells, rabeprazole is protonated, accumulates, and is transformed to an active sulfonamide.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ACIPHEX

Approved Use

ACIPHEX is a proton-pump inhibitor (PPI) indicated in adults for: Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) ( ) 1.1 Maintenance of Healing of Erosive or Ulcerative GERD ( ) 1.2 Treatment of Symptomatic GERD ( ) 1.3 Healing of Duodenal Ulcers ( ) 1.4 Eradication to Reduce the Risk of Duodenal Ulcer Recurrence ( ) Helicobacter pylori 1.5 Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome ( ) 1.6 In adolescent patients 12 years of age and older for: Short-term treatment of Symptomatic GERD ( ) 1.7 In pediatric patients 1 to 11 years of age for: Treatment of GERD ( ) 1.8 1.1 Healing of Erosive or Ulcerative GERD in Adults ACIPHEX is indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD). For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of ACIPHEX may be considered. 1.2 Maintenance of Healing of Erosive or Ulcerative GERD in Adults ACIPHEX is indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (GERD Maintenance). Controlled studies do not extend beyond 12 months. 1.3 Treatment of Symptomatic GERD in Adults ACIPHEX is indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with GERD in adults 1.4 Healing of Duodenal Ulcers in Adults ACIPHEX is indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers. Most patients heal within four weeks. 1.5 Eradication to Reduce the Risk of Duodenal Ulcer Recurrence in Adults Helicobacter pylori ACIPHEX in combination with amoxicillin and clarithromycin as a three drug regimen, is indicated for the treatment of patients with infection and duodenal ulcer disease (active or history within the past 5 years) to eradicate . Eradication of has been shown to reduce the risk of duodenal ulcer recurrence [ and

Launch Date

1999
Primary
ACIPHEX

Approved Use

ACIPHEX is a proton-pump inhibitor (PPI) indicated in adults for: Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) ( ) 1.1 Maintenance of Healing of Erosive or Ulcerative GERD ( ) 1.2 Treatment of Symptomatic GERD ( ) 1.3 Healing of Duodenal Ulcers ( ) 1.4 Eradication to Reduce the Risk of Duodenal Ulcer Recurrence ( ) Helicobacter pylori 1.5 Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome ( ) 1.6 In adolescent patients 12 years of age and older for: Short-term treatment of Symptomatic GERD ( ) 1.7 In pediatric patients 1 to 11 years of age for: Treatment of GERD ( ) 1.8 1.1 Healing of Erosive or Ulcerative GERD in Adults ACIPHEX is indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD). For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of ACIPHEX may be considered. 1.2 Maintenance of Healing of Erosive or Ulcerative GERD in Adults ACIPHEX is indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (GERD Maintenance). Controlled studies do not extend beyond 12 months. 1.3 Treatment of Symptomatic GERD in Adults ACIPHEX is indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with GERD in adults 1.4 Healing of Duodenal Ulcers in Adults ACIPHEX is indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers. Most patients heal within four weeks. 1.5 Eradication to Reduce the Risk of Duodenal Ulcer Recurrence in Adults Helicobacter pylori ACIPHEX in combination with amoxicillin and clarithromycin as a three drug regimen, is indicated for the treatment of patients with infection and duodenal ulcer disease (active or history within the past 5 years) to eradicate . Eradication of has been shown to reduce the risk of duodenal ulcer recurrence [ and

Launch Date

1999
Primary
ACIPHEX

Approved Use

ACIPHEX is a proton-pump inhibitor (PPI) indicated in adults for: Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) ( ) 1.1 Maintenance of Healing of Erosive or Ulcerative GERD ( ) 1.2 Treatment of Symptomatic GERD ( ) 1.3 Healing of Duodenal Ulcers ( ) 1.4 Eradication to Reduce the Risk of Duodenal Ulcer Recurrence ( ) Helicobacter pylori 1.5 Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome ( ) 1.6 In adolescent patients 12 years of age and older for: Short-term treatment of Symptomatic GERD ( ) 1.7 In pediatric patients 1 to 11 years of age for: Treatment of GERD ( ) 1.8 1.1 Healing of Erosive or Ulcerative GERD in Adults ACIPHEX is indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD). For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of ACIPHEX may be considered. 1.2 Maintenance of Healing of Erosive or Ulcerative GERD in Adults ACIPHEX is indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (GERD Maintenance). Controlled studies do not extend beyond 12 months. 1.3 Treatment of Symptomatic GERD in Adults ACIPHEX is indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with GERD in adults 1.4 Healing of Duodenal Ulcers in Adults ACIPHEX is indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers. Most patients heal within four weeks. 1.5 Eradication to Reduce the Risk of Duodenal Ulcer Recurrence in Adults Helicobacter pylori ACIPHEX in combination with amoxicillin and clarithromycin as a three drug regimen, is indicated for the treatment of patients with infection and duodenal ulcer disease (active or history within the past 5 years) to eradicate . Eradication of has been shown to reduce the risk of duodenal ulcer recurrence [ and

Launch Date

1999
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.54 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RABEPRAZOLE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.406 μg/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RABEPRAZOLE unknown
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
2.5 μg/mL
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RABEPRAZOLE unknown
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2.15 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RABEPRAZOLE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.809 μg × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RABEPRAZOLE unknown
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
5.212 μg × h/mL
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RABEPRAZOLE unknown
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.46 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RABEPRAZOLE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1.02 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RABEPRAZOLE unknown
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
1.21 h
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RABEPRAZOLE unknown
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
40 mg single, oral
Recommended
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.670
healthy, 22.5 ± 3.9
n = 8
Health Status: healthy
Age Group: 22.5 ± 3.9
Sex: M
Population Size: 8
Sources: Page: p.670
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.978
unhealthy, 41
n = 20
Health Status: unhealthy
Condition: Gastroesophageal reflux disease
Age Group: 41
Sex: M+F
Population Size: 20
Sources: Page: p.978
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.1337
unhealthy, 45.5
n = 68
Health Status: unhealthy
Condition: Gastroesophageal reflux disease
Age Group: 45.5
Sex: M+F
Population Size: 68
Sources: Page: p.1337
PubMed

PubMed

TitleDatePubMed
[Pariet in eradication therapy plans].
2002
[Seven-day antihelicobacter therapy of duodenal ulcer associated with Helicobacter pylori and prospects for treating patients].
2002
[Effectiveness of pariet (rabeprazole) in the treatment of gastroesophageal reflux disease (at the reflux-esophagitis stage)].
2002
Patients have treatment preferences: a multicentre, double-blind, crossover study comparing rabeprazole and omeprazole.
2002
[Regeneration of the esophagus epitheliocytes. Evaluation of pariet efficacy in the treatment of patients with reflux esophagitis].
2002
[Inhibitors of proton pump in the treatment of non-ulcer functional dyspepsia of the reflux-like type].
2002
Rabeprazole: quest for the best PPI.
2002
The effects of rabeprazole on parietal cells and enterochromaffin-like cells in rats: a comparison with omeprazole.
2002
[Regeneration of the gastric epitheliocytes during treatment of duodenal ulcer with pariet].
2002 Apr
Proton pump inhibitor modifies inflammatory reaction in human gastric mucosa infected by Helicobacter pylori.
2002 Apr
Levofloxacin based regimens for the eradication of Helicobacter pylori.
2002 Dec
Treatment and management of Helicobacter pylori infection.
2002 Dec
The pharmacology and clinical relevance of proton pump inhibitors.
2002 Dec
[Cause and prevention of nocturnal gastric acid breakthrough].
2002 Feb
[Proton pump inhibitors: Rabeprazole].
2002 Feb
[Continuation of acid suppression therapy after H. pylori eradication].
2002 Feb
[Minocycline-containing eradication therapy for patients with clarithromycin-resistant Helicobacter pylori infection].
2002 Feb
[Second line treatment regimen of PPI + AMPC + MNZ for patients with clarithromycin-resistant Helicobacter pylori infection].
2002 Feb
[High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy: CYP2C19 polymorphism].
2002 Feb
[Proton pump inhibitor-based quadruple therapy regimen for Helicobacter pylori infection].
2002 Feb
[Dual therapy for Helicobacter pylori resistance to anti microbial agents].
2002 Feb
[Pharma-clinics medication of the month. Rabeprazole (Pariet)].
2002 Jan
Gateways to clinical trials.
2002 Jan-Feb
[Evaluation of efficacy, safety and tolerability rabeprazole in treatment of acid-peptic diseases ].
2002 Jan-Mar
Rabeprazole.
2002 Jan-Mar
Proton pump inhibitors--differences emerge in hepatic metabolism.
2002 Jul
Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
2002 Jul
Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects.
2002 Jul
Measuring symptom distress and health-related quality of life in clinical trials of gastroesophageal reflux disease treatment: further validation of the Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS).
2002 Jul
Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
2002 Jul
The efficacy of lafutidine in improving preoperative gastric fluid property: a comparison with ranitidine and rabeprazole.
2002 Jul
Proton pump inhibitors: an update.
2002 Jul 15
Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials.
2002 Jul 15
Polymorphism of CYP2C19 and gastric emptying in patients with proton pump inhibitor-resistant gastric ulcers.
2002 Jul-Aug
Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial.
2002 Jun
Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis.
2002 Jun
Primary hyperparathyroidism with duodenal ulcer and H. pylori infection.
2002 May
Combination drug therapy for gastroesophageal reflux disease.
2002 May
A modification of the quininium resin test for assessing gastric acidity.
2002 May
Rabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux disease.
2002 Nov
Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation.
2002 Nov
Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study.
2002 Nov
Restoration of acid secretion following treatment with proton pump inhibitors.
2002 Nov
Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin.
2002 Nov
A new serum antibody test kit (E plate) for evaluation of Helicobacter pylori eradication.
2002 Oct
Sequential eradicating therapy: a treatment that does not discriminate Helicobacter pylori strains in patients with nonulcer dyspepsia?
2002 Oct
Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
2002 Oct
Gateways to Clinical Trials.
2002 Sep
[The short term effect of rabeprazol versus omeprazole on symptom relief of duodenal ulcer].
2002 Sep
Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions.
2002 Sep
Patents

Sample Use Guides

Erosive or Ulcerative Gastroesophageal Reflux Disease: 20 mg delayed-release tablet to be taken once daily for four to eight weeks. Duodenal Ulcers: 20 mg delayed-release tablet to be taken once daily after the morning meal for a period up to four weeks. Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome: The recommended adult oral starting dose is 60 mg once a day. Doses should be adjusted to individual patient needs and should continue for as long as clinically indicated. Some patients may require divided doses. Doses up to 100 mg QD and 60 mg BID have been administered
Route of Administration: Oral
The MICs of rabeprazole sodium (RPZ) against 133 clinical Helicobacter pylori strains revealed a higher degree of activity. The 133 H. pylori strains tested were recent clinical isolates from different patients with chronic gastritis and gastric and/or duodenal ulcer. The final concentrations prepared in the wells of the microplates were from 0.031 to 64 μg/ml for RPZ.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:44:20 GMT 2023
Edited
by admin
on Fri Dec 15 15:44:20 GMT 2023
Record UNII
32828355LL
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RABEPRAZOLE
HSDB   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
LY-307640
Code English
E-3810 (PPI)
Code English
1H-BENZIMIDAZOLE, 2-(((4-(3-METHOXYPROPOXY)-3-METHYL-2-PYRIDINYL)METHYL)SULFINYL)-
Systematic Name English
E3810
Code English
rabeprazole [INN]
Common Name English
LY307640
Code English
RABEPRAZOLE [VANDF]
Common Name English
RABEPRAZOLE [MI]
Common Name English
PARIPRAZOLE
Common Name English
Rabeprazole [WHO-DD]
Common Name English
ERALOC
Brand Name English
RABEPRAZOLE [HSDB]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175525
Created by admin on Fri Dec 15 15:44:20 GMT 2023 , Edited by admin on Fri Dec 15 15:44:20 GMT 2023
LIVERTOX NBK548154
Created by admin on Fri Dec 15 15:44:20 GMT 2023 , Edited by admin on Fri Dec 15 15:44:20 GMT 2023
WHO-ATC A02BC54
Created by admin on Fri Dec 15 15:44:20 GMT 2023 , Edited by admin on Fri Dec 15 15:44:20 GMT 2023
NDF-RT N0000000147
Created by admin on Fri Dec 15 15:44:20 GMT 2023 , Edited by admin on Fri Dec 15 15:44:20 GMT 2023
WHO-ATC A02BC04
Created by admin on Fri Dec 15 15:44:20 GMT 2023 , Edited by admin on Fri Dec 15 15:44:20 GMT 2023
WHO-VATC QA02BC04
Created by admin on Fri Dec 15 15:44:20 GMT 2023 , Edited by admin on Fri Dec 15 15:44:20 GMT 2023
NCI_THESAURUS C29723
Created by admin on Fri Dec 15 15:44:20 GMT 2023 , Edited by admin on Fri Dec 15 15:44:20 GMT 2023
Code System Code Type Description
EVMPD
SUB10229MIG
Created by admin on Fri Dec 15 15:44:20 GMT 2023 , Edited by admin on Fri Dec 15 15:44:20 GMT 2023
PRIMARY
EPA CompTox
DTXSID3044122
Created by admin on Fri Dec 15 15:44:20 GMT 2023 , Edited by admin on Fri Dec 15 15:44:20 GMT 2023
PRIMARY
INN
7112
Created by admin on Fri Dec 15 15:44:20 GMT 2023 , Edited by admin on Fri Dec 15 15:44:20 GMT 2023
PRIMARY
SMS_ID
100000080304
Created by admin on Fri Dec 15 15:44:20 GMT 2023 , Edited by admin on Fri Dec 15 15:44:20 GMT 2023
PRIMARY
LACTMED
Rabeprazole
Created by admin on Fri Dec 15 15:44:20 GMT 2023 , Edited by admin on Fri Dec 15 15:44:20 GMT 2023
PRIMARY
IUPHAR
7290
Created by admin on Fri Dec 15 15:44:20 GMT 2023 , Edited by admin on Fri Dec 15 15:44:20 GMT 2023
PRIMARY
MESH
C063129
Created by admin on Fri Dec 15 15:44:20 GMT 2023 , Edited by admin on Fri Dec 15 15:44:20 GMT 2023
PRIMARY
DRUG BANK
DB01129
Created by admin on Fri Dec 15 15:44:20 GMT 2023 , Edited by admin on Fri Dec 15 15:44:20 GMT 2023
PRIMARY
WIKIPEDIA
RABEPRAZOLE
Created by admin on Fri Dec 15 15:44:20 GMT 2023 , Edited by admin on Fri Dec 15 15:44:20 GMT 2023
PRIMARY
CHEBI
8768
Created by admin on Fri Dec 15 15:44:20 GMT 2023 , Edited by admin on Fri Dec 15 15:44:20 GMT 2023
PRIMARY
CAS
117976-89-3
Created by admin on Fri Dec 15 15:44:20 GMT 2023 , Edited by admin on Fri Dec 15 15:44:20 GMT 2023
PRIMARY
PUBCHEM
5029
Created by admin on Fri Dec 15 15:44:20 GMT 2023 , Edited by admin on Fri Dec 15 15:44:20 GMT 2023
PRIMARY
HSDB
7321
Created by admin on Fri Dec 15 15:44:20 GMT 2023 , Edited by admin on Fri Dec 15 15:44:20 GMT 2023
PRIMARY
MERCK INDEX
m9476
Created by admin on Fri Dec 15 15:44:20 GMT 2023 , Edited by admin on Fri Dec 15 15:44:20 GMT 2023
PRIMARY Merck Index
NCI_THESAURUS
C29410
Created by admin on Fri Dec 15 15:44:20 GMT 2023 , Edited by admin on Fri Dec 15 15:44:20 GMT 2023
PRIMARY
RXCUI
114979
Created by admin on Fri Dec 15 15:44:20 GMT 2023 , Edited by admin on Fri Dec 15 15:44:20 GMT 2023
PRIMARY RxNorm
DAILYMED
32828355LL
Created by admin on Fri Dec 15 15:44:20 GMT 2023 , Edited by admin on Fri Dec 15 15:44:20 GMT 2023
PRIMARY
DRUG CENTRAL
2350
Created by admin on Fri Dec 15 15:44:20 GMT 2023 , Edited by admin on Fri Dec 15 15:44:20 GMT 2023
PRIMARY
ChEMBL
CHEMBL1219
Created by admin on Fri Dec 15 15:44:20 GMT 2023 , Edited by admin on Fri Dec 15 15:44:20 GMT 2023
PRIMARY
FDA UNII
32828355LL
Created by admin on Fri Dec 15 15:44:20 GMT 2023 , Edited by admin on Fri Dec 15 15:44:20 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
BINDER->LIGAND
BINDING
TARGET -> INHIBITOR
ENANTIOMER -> RACEMATE
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE -> PARENT
MAJOR
METABOLITE ACTIVE -> PARENT
METABOLITE ACTIVE -> PRODRUG
METABOLITE -> PARENT
METABOLITE ACTIVE -> PARENT
reduced mainly via a non-enzymatic pathway to thioether-rabeprazole (thioether-RPZ), with only minor CYP2C19 and CYP3A4 involvement
MAJOR
METABOLITE ACTIVE -> PRODRUG
Related Record Type Details
IMPURITY -> PARENT
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC